Sigue a Immunexpress en Twitter [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=854844606&u=...] y LinkedIn [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=3064814854&u...].
*Immunexpress tiene licencia para usar la marca comercial Idylla(TM) de Biocartis NV.
Contacto para los medios de comunicación: Maggie BellerRusso Partners, LLC+1(646) 942-5631Maggie.beller@russopartnersllc.com[mailto:Maggie.beller@russopartnersllc.com]
(1)Zhou, F., et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3 [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=1684565204&u...]
Logo -- https://mma.prnewswire.com/media/1033289/Immunexpress_Inc.jp... [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=3177164429&u...]
Sitio Web: http://www.immunexpress.com/